Life Less Interrupted with Lebrikizumab
Overview
Professor Thaçi explains how EBGLYSS gives patients with moderate-to-severe AD
long-term, To Live a Life Less Interrupted with Lebrikizumab, to provide them Flare
Less, Apply Less and Dose Less experience.
This Class for
- Clinical Pharmacy
- Pharmacy
- Physician
- Resident / Fellow
What I will learn?
- Explain flare free control in AD
- Describe how EBGLYSS works through IL-13
- Review of the long-term results:
-86% of patients remained completely flare free by Year 1,
maintained in 71% by Year 3.
-Skin clearance with deep remission (EASI 90/100) held up
over 3 years.
-Itch relief held up over 2 years. - Highlight monthly dosing and the favorable safety profile.
Disclaimer
This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)
For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com
24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1
For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com
For further information, please contact:
Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.comCMAT-53695
Related Classes
- Learnings from AA experience
- Stable Response to IL-13 and IL-13/4 Inhibitor Treatment in Moderate-to- Severe AD.
- How Can Response Patterns to Olumiant Inform Clinical Decision-Making in Severe Alopecia Areata?
- Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A Novel Treatment Option for Patients ≥12 Years
- Atopic Dermatitis in Elderly Patients: Discussing the Safety of Lebrikizumab in an 86-Year-Old Patient.
- Key IL-13 Skin and Itch Data in Moderate-to-Severe AD.
- Atopic Dermatitis in Visible Areas Is a Real Challenge!
- Depth of Response & Stability of Response of Lebrikizumab